1. Medtech Insight

Exec Chat: J&J DePuy Synthes’ Sharrolyn Josse Outlines Strategy For VELYS Digital Surgery

 
• By Marion Webb

In an interview with Medtech Insight, Sharrolyn Josse, worldwide president of VELYS Digital Surgery and Capital at Johnson & Johnson’s DePuy Synthes unit, outlines strategies that are driving the present and future VELYS robotic-assisted solution and its connected technologies.

Digital Future

This January, Johnson & Johnson (Pty) LtdDePuy Synthes announced it received US Food and Drug Administration 510(k) clearance for the VELYS Robotic-Assisted Solution designed for use with the Attune knee system. The solution simplifies surgeon’s workflow around total knee replacement and is part of the broader VELYS digital surgery platform of connected technologies, which can leverage data insights for patients, surgeons and health systems.

J&J obtained the VELYS technology by acquiring Orthotaxy SAS, a French developer of software-based surgical technologies, for an undisclosed sum in 2018. (Also see "J&J Adds To Robotic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.